Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

sing was applied according to the study protocol. In both edoxaban treatment arms, the edoxaban dose was halved for patients with clinical factors that were known to increase the risk of bleeding (renal impairment, low body weight or concomitant use of certain P-glycoprotein inhibitors).1, 2 Patients receiving a reduced edoxaban dose in the 60 mg treatment arm had an annual incidence of stroke or SEE of 2.32% versus 2.68% for warfarin and a significantly reduced major bleeding incidence of 3.05% versus 4.85%. Patients receiving a reduced edoxaban dose in the 30 mg treatment arm had an annual incidence of stroke or SEE of 3.14% versus 2.68% for warfarin and a significantly reduced major bleeding incidence of 1.50% versus 4.85%.2

"The results from the ENGAGE AF-TIMI 48 trial showed that edoxaban may provide a new treatment option for the prevention of stroke or systemic embolic events that demonstrates comparable efficacy to warfarin, while significantly reducing the risk of major bleeding. In addition, we identified an appropriate dose regimen for patients with clinical factors such as renal impairment and low body weight," said Robert Giugliano, MD, SM, FAHA, FACC, Senior Investigator with the TIMI Study Group, Physician Cardiovascular Medicine, Brigham and Women's Hospital, Associate Professor of Medicine, Harvard Medical School, and Co-Global Lead Investigator of the ENGAGE AF-TIMI 48 trial. "In conducting this landmark trial we sought to provide clinicians with robust data, evident by the trial size and follow-up, high percentage of time in therapeutic range for the warfarin treatment arm, and very low rate of missing data. In addition, we specifically designed a comprehensive transition plan to protect patients from the undue risk of stroke and bleeding when switching to open-label anticoagulation at the end of the trial."

"The edoxaban clinical trial program, the largest in the history of Daiichi
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... 21, 2014 CVS Caremark Corporation (NYSE: ... Yields and consideration payable in connection with its previously announced ... 2014 for (1) any and all of its 6.250% Senior ... up to a maximum amount of its 6.125% Senior Notes ... Notes due 2017 (collectively, the "Maximum Tender Offer Notes" and ...
(Date:8/21/2014)... 21, 2014 Professional Compounding Centers of ... by awarding the three best scientific presentations at ... conference . The Formulating Better Medicines for ... Athens, Greece , includes dozens ... professionals, from which three winners will be selected ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... THE WOODLANDS, Texas, Aug. 9, 2011 ... ), a biopharmaceutical company focused on discovering breakthrough ... data from its recently completed Phase 2 study ... etiprate. Carcinoid syndrome is a chronic condition caused ...
... SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 9, 2011 ... and Eisai Inc. announced today results from ... mammary tumor diagnoses from a two-year rat carcinogenicity study ... the lorcaserin Complete Response Letter (CRL), which questioned the ...
Cached Medicine Technology:Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 2Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 3Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 4Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 5Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 2Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 3Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 4Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 5Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 6
(Date:8/21/2014)... 21, 2014 The report "Industrial ... Pollutant Control System (FGD, DeNOx, Particulate Control, Mercury ... Steel, Chemical & Others) - Global Trends & ... industrial flue gas treatment systems & services market ... size in terms of value. The industrial flue ...
(Date:8/21/2014)... Revista, a one-stop source for ... data, is “on a roll.” Today, the Annapolis-based ... the Southeast, Mid-Atlantic and Midwest areas of the ... widely available, comprehensive medical property database tracking these ... properties, including existing and recently added, is 34,549. ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, 2014 ... dropped nearly 12 percent in the last decade, a new ... of teens using indoor tanning beds barely decreased. Both indoor ... skin cancers, including deadly melanomas, the researchers noted. "Unfortunately, ... who reported wearing sunscreen, from 67.7 percent in 2001 to ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... 2014 When children go back to school, ... cause them to become sick and risk missing school. It ... help them fight these germs to ensure a successful school ... just that with its XFactor program. , The XFactor program ... multi-vitamins. Children ages 4 and up can receive 30-day supplies ...
Breaking Medicine News(10 mins):Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:MedX Pharmacy Helps with Back to School Preparation 2
... Calif. - A single dose of antibiotics can significantly ... vaginal tissues during many births, according to researchers at ... School of Medicine and Santa Clara Valley Medical Center. ... simple treatment can prevent many of the short- and ...
... Mylan Inc. (NYSE: MYL ),today announced that ... U.S. Food and Drug Administration (FDA) for its,Abbreviated New ... 10,mg., Zaleplon Capsules are the generic version of ... $88 million for,the 12 months ending March 31, 2008, ...
... handful of measures are,effective, NEWTOWN, Conn., June ... and policy makers about the importance of choosing,the ... measurement,efforts, Bridges to Excellence(TM) (BTE) conducted a review ... physicians meet certain ambulatory,care quality measures. The study, ...
... Company donates $100,000 to American Red Cross, INDIANAPOLIS, ... arm of Eli Lilly and Company (NYSE: LLY ... assistance to aid,Indiana tornado and flood victims. More than ... Gov. Mitch Daniels as a result of deadly,tornadoes and ...
... Va., June 9 The National,Community Pharmacists ... Pharmacists (IACP) are collaborating to increase the,legislative ... in compounding.,IACP has established a satellite office ... Director of Public Affairs, Sarah R. Dodge. ...
... N.J., June 9 Wyeth (NYSE: WYE ... Goldman Sachs Twenty-Ninth,Annual Global Healthcare Conference on June ... Wyeth will be Bernard Poussot, President and Chief,Executive ... live for investors at, http://www.wyeth.com and available ...
Cached Medicine News:Health News:Antibiotics can prevent wound complications of childbirth, Stanford/Packard study finds 2Health News:Bridges to Excellence Study Assesses Clinical and Financial Impact of Physician Quality Measures 2Health News:Lilly to Provide Aid to Indiana Tornado and Flood Victims 2Health News:Pharmacist Associations Partner to Increase the Voice of Pharmacy 2
... plate acc. to Matzen is used for ... (HWS) with the exception of C0-C2. The ... fusion length until the bone transplant has ... the vertebral bodies, if possible along the ...
... The SC-Acufix anterior cervical plate system ... a patented, integrated swivel, which provides for ... and prevents bone screw disengagement or backout. ... a secondary locking screw. Simply implant your ...
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
... consisting of one part only, is made of ... compressed Polyamide may be rotated and moved as ... sizes and shapes, as well. Moreover they secure ... in caudal direction, which is one of the ...
Medicine Products: